Synthesis and evaluation of an injectable everolimus prodrug
- 1 March 2017
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (5) , 1175-1178
Abstract
No abstract availableKeywords
Funding Information
- Key Science and Technology Innovation Team of Zhejiang Province (2013TD10)
This publication has 17 references indexed in Scilit:
- Safety of Everolimus in Patients Younger than 3 Years of Age: Results from EXIST-1, a Randomized, Controlled Clinical TrialThe Journal of Pediatrics, 2016
- One step forward, two steps back: The story of everolimus in advanced breast cancerThe Breast, 2015
- Everolimus and pancreatic neuroendocrine tumors (PNETs): Activity, resistance and how to overcome itInternational Journal of Surgery, 2015
- Long-Term Everolimus Treatment in Individuals With Tuberous Sclerosis Complex: A Review of the Current LiteraturePediatric Neurology, 2015
- Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: Pharmacokinetic considerations and clinical implicationsCancer Treatment Reviews, 2013
- Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non–Small-Cell Lung CancerJournal of Thoracic Oncology, 2013
- Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategyJournal of Clinical Investigation, 2011
- Research and innovation in the development of everolimus for oncologyExpert Opinion on Drug Discovery, 2011
- Phase 3 trial of everolimus for metastatic renal cell carcinomaCancer, 2010
- Clinical Pharmacokinetics of EverolimusClinical Pharmacokinetics, 2004